Alison Sechrest

Alison Sechrest

Associate

Alison Sechrest is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law.

During law school, Alison was a law clerk in the University of California’s Office of the General Counsel in the Health Affairs and Technology Group.

Experience

Alison Sechrest is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law.

During law school, Alison was a law clerk in the University of California’s Office of the General Counsel in the Health Affairs and Technology Group.

Education

J.D., Duke University School of Law, 2022Cum Laude; Staff Editor, Duke Law Journal
M.A., Bioethics and Science Policy, Duke University Graduate School, 2022
B.S., Psychobiology, University of California, Los Angeles, 2018
Magna Cum Laude

Admissions

State Bar of California

Credentials

Education

J.D., Duke University School of Law, 2022Cum Laude; Staff Editor, Duke Law Journal
M.A., Bioethics and Science Policy, Duke University Graduate School, 2022
B.S., Psychobiology, University of California, Los Angeles, 2018
Magna Cum Laude

Admissions

State Bar of California

Corporate

Recent Insights

Client Highlights

On April 22, 2024, Rubedo Life Sciences, a Sunnyvale, CA-based biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells that drive age-related diseases, closed a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors. Wilson Sonsini Goodrich & Rosati advised Rubedo on the transaction.

Learn More

Client Highlights

On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.

Learn More